Anika Therapeutics Inc (NAS:ANIK)

$ 17.35 -0.2 (-1.14%) Market Cap: 254.10 Mil Enterprise Value: 219.27 Mil PE Ratio: 0 PB Ratio: 1.42 GF Score: 70/100

Q3 2024 Anika Therapeutics Inc Earnings Call Transcript
Oct 31, 2024

$17.11 (-30.67%)

Earnings
Q2 2024 Anika Therapeutics Inc Earnings Call Transcript
Aug 08, 2024

$25.68 (-1.04%)

Earnings
Q1 2024 Anika Therapeutics Inc Earnings Call Transcript
May 08, 2024

$28.47 (+0.39%)

Earnings
Q4 2023 Anika Therapeutics Inc Earnings Call Transcript
Mar 13, 2024

$25.4 (-1.51%)

Earnings
Q3 2023 Anika Therapeutics Inc Earnings Call Transcript
Nov 02, 2023

$18.99 (-3.46%)

Earnings
Q2 2023 Anika Therapeutics Inc Earnings Call Transcript
Aug 08, 2023

$21.05

Earnings
Q1 2023 Anika Therapeutics Inc Earnings Call Transcript
May 09, 2023

$25.29 (-2.66%)

Earnings
Anika Therapeutics Inc at Needham Healthcare Conference (Virtual) Transcript
Apr 20, 2023
Q4 2022 Anika Therapeutics Inc Earnings Call Transcript
Mar 06, 2023

$28.87 (-8.61%)

Earnings
Q3 2022 Anika Therapeutics Inc Earnings Call Transcript
Nov 08, 2022

$27.37 (-7.28%)

Earnings
Q2 2022 Anika Therapeutics Inc Earnings Call Transcript
Aug 03, 2022

$24.68 (+2.32%)

Earnings
Q1 2022 Anika Therapeutics Inc Earnings Call Transcript
May 05, 2022

$20.56 (-6.97%)

Earnings
Anika Therapeutics Inc at Needham Healthcare Conference (Virtual) Transcript
Apr 14, 2022
Q4 2021 Anika Therapeutics Inc Earnings Call Transcript
Mar 08, 2022

$30.6 (-1.89%)

Earnings
Q3 2021 Anika Therapeutics Inc Earnings Call Transcript
Nov 04, 2021

$43.32 (-0.85%)

Earnings
Anika Therapeutics Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Sep 15, 2021
Q2 2021 Anika Therapeutics Inc Earnings Call Transcript
Aug 05, 2021

$41.09 (+2.60%)

Earnings
Anika Therapeutics Inc Host its Virtual Investor Day Transcript
Jun 03, 2021
Anika Therapeutics Inc Presenting at UBS Global Healthcare Virtual Conference Transcript
May 25, 2021
Q1 2021 Anika Therapeutics Inc Earnings Call Transcript
May 06, 2021

$40.78 (-1.57%)

Earnings
Q4 2020 Anika Therapeutics Inc Earnings Call Transcript
Mar 04, 2021

$38.13 (-1.47%)

Earnings
Q3 2020 Anika Therapeutics Inc Earnings Call Transcript
Nov 04, 2020

$36.77 (+4.94%)

Earnings
Anika Therapeutics Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Sep 17, 2020
Q2 2020 Anika Therapeutics Inc Earnings Call Transcript
Jul 30, 2020

$37.17 (+2.45%)

Earnings
Anika Therapeutics Inc Annual Shareholders Meeting Transcript
Jun 16, 2020
Anika Therapeutics Inc at UBS Global Healthcare Conference (Virtual) Transcript
May 19, 2020
Q1 2020 Anika Therapeutics Inc Earnings Call Transcript
May 07, 2020

$34.55 (+1.95%)

Earnings
Q4 2019 Anika Therapeutics Inc Earnings Call Transcript
Feb 20, 2020

$42 (-1.34%)

Earnings
Anika Therapeutics Inc to Acquire PARCUS MEDICAL L L C and Arthrosurface Inc Call Transcript
Jan 08, 2020
Q3 2019 Anika Therapeutics Inc Earnings Call Transcript
Oct 24, 2019

$54.27 (-2.30%)

Earnings
Anika Therapeutics Inc Corporate Analyst Meeting Transcript
Sep 18, 2019
Anika Therapeutics Inc at Morgan Stanley Healthcare Conference Transcript
Sep 10, 2019
Q2 2019 Anika Therapeutics Inc Earnings Call Transcript
Jul 24, 2019

$40.82 (+0.20%)

Earnings
Q1 2019 Anika Therapeutics Inc Earnings Call Transcript
May 02, 2019

$33.96 (+3.57%)

Earnings

Q1 2024 Anika Therapeutics Inc Earnings Call Transcript

May 08, 2024 / 09:30PM GMT

Release Date Price: $28.47 (+0.39%)

Transcript 10-Q8-K

Operator

Good evening, ladies and gentlemen, and welcome to Anika's First Quarter 2024 earnings conference call. At this time, all lines are in a listen only mode. Following the presentation, we will conduct a question and answer session. Instructions will be provided at that time for you to queue up for a question. If anyone has any difficulties hearing the conference, please press star zero for operator assistance at any time. I would like to remind everyone that this call is being recorded. I will now turn the call over to Mark Namaroff, Vice President Investor Relations, ESG and corporate communications. Please proceed.

Mark Namaroff

Anika Therapeutics, Inc. - VP of Investor Relations, ESG, and Corporate Communications

Thank you. Good afternoon, everyone. Thank you for joining us for Anika's First Quarter 2020 for our conference call and webcast. Our Q1 earnings press release was issued after the close of the market today and is available on our Investor Relations website located at Anika.com as are the supplementary PowerPoint slides that will be used for the

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.